Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

Abstract Coronavirus disease 2019 (COVID-19) vaccine trials provide valuable insight into
the safety and efficacy of vaccines, with individually randomized, placebo-controlled trials …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

Billions of doses of COVID-19 vaccines have been administered globally, dramatically
reducing SARS-CoV-2 incidence and severity in some settings. Many studies suggest …

Nowadays, the vaccination with COVID-19 vaccines is being promoted worldwide,
professionals and common people are very concerned about the efficacy and safety of …

Background Knowing whether COVID-19 vaccine effectiveness wanes is crucial for
informing vaccine policy, such as the need for and timing of booster doses. We aimed to …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …

Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …

The world needs more vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), in order to …

Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …